Immunovant (NASDAQ:IMVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling [Yahoo! Finance]
Immunovant (NASDAQ:IMVT) had its price target raised by analysts at Truist Financial Corporation from $16.00 to $22.00. They now have a "hold" rating on the stock.
Immunovant (NASDAQ:IMVT) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)